Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Martin
About this trial
The study aims to improve the prediction and early detection of post-transplant diabetes mellitus (PTDM) in kidney transplant recipients. The investigators are investigating whether specific microRNA profiles measured 3 months after transplantation can reliably predict the development of PTDM within the following one to two years.
Additionally, the investigators are evaluating how traditional risk factors-such as age, immunosuppressive therapy, obesity, and infections like CMV-interact with these microRNA markers.
The ultimate goal of this research is to identify early indicators of blood sugar issues, enabling timely interventions to improve health outcomes and personalize patient care after kidney transplantation.
Eligibility criteria
Qualifiers
Adult patients undergoing kidney transplantation.
Absence of pre-existing type 1 or type 2 diabetes mellitus.
Willingness to provide informed consent and comply with study procedures.
Disqualifiers
Pre-existing type 1 or type 2 diabetes mellitus.
Previous organ transplantation.
Severe comorbidities that could confound the assessment of PTDM (e.g., pancreatic disease).
Inability to provide informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
130 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov